Lumosa Therapeutics CoROCO:6535 +9.58%72 Current Ratio is 7.37 as of Dec. 2025, which is 3% above its 10-year median of 7.15. GuruFocus rates ROCO:6535 with a GF Score™ of 72/100 and a GF Value™ of NT$130.93 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 1,410 Biotechnology companies, Lumosa Therapeutics Co ranks better than 69.72% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Lumosa Therapeutics Co's current ratio for the quarter that ended in Dec. 2025 was 7.37.
Lumosa Therapeutics Co has a current ratio of 7.37. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Lumosa Therapeutics Co's Current Ratio or its related term are showing as below:
ROCO:6535'
s Current Ratio Range Over the Past 10 Years
Min: 3.52 Med: 7.15 Max: 18.76
Current: 7.37
During the past 13 years, Lumosa Therapeutics Co's highest Current Ratio was 18.76. The lowest was 3.52. And the median was 7.15.
ROCO:6535's Current Ratio is ranked better than 69.72% of 1410
companies
in the Biotechnology industry
Industry Median: 3.9
vs ROCO:6535: 7.37
Lumosa Therapeutics Co (ROCO:6535) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Lumosa Therapeutics Co Current Ratio Related Terms
Lumosa Therapeutics Co Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6535 vs VRTX, REGN, ALNY: Current Ratio Comparison
For the Biotechnology subindustry, Lumosa Therapeutics Co's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lumosa Therapeutics Co Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lumosa Therapeutics Co's Current Ratio distribution charts can be found below:
* The bar in red indicates where Lumosa Therapeutics Co's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lumosa Therapeutics Co (ROCO:6535) has a Current Ratio of 7.37 as of Dec. 2025. This is near median its historical median of 7.15. Over the past decade, Lumosa Therapeutics Co's Current Ratio has ranged from 3.52 to 18.76. According to the industry distribution chart, Lumosa Therapeutics Co ranks #427 out of 1410 companies in the Biotechnology industry, placing it in the top 30.3%.
Is Lumosa Therapeutics Co's Current Ratio too high?
Lumosa Therapeutics Co's current Current Ratio of 7.37 is near median its 10-year median of 7.15. Over the past 10 years, this metric has ranged from a low of 3.52 to a high of 18.76. The Biotechnology industry median Current Ratio is 3.90. Lumosa Therapeutics Co's value of 7.37 is 89% above this industry median. Based on the distribution chart, Lumosa Therapeutics Co ranks #427 out of 1410 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Lumosa Therapeutics Co has a GF Score™ of 72/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Lumosa Therapeutics Co's Current Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Lumosa Therapeutics Co ranks #427 out of 1410 companies for Current Ratio. This puts Lumosa Therapeutics Co in the upper half of its industry. The industry median Current Ratio is 3.90. Lumosa Therapeutics Co's value of 7.37 is 89% above this benchmark. Historically, Lumosa Therapeutics Co's own Current Ratio has ranged from 3.52 to 18.76 over the past decade. While the company's 10-year median is 7.15 vs. the industry median of 3.90, Lumosa Therapeutics Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.90, based on 1,410 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lumosa Therapeutics Co's current Current Ratio of 7.37 is 89% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lumosa Therapeutics Co's current Current Ratio is 7.37, which is near median its own 10-year median of 7.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lumosa Therapeutics Co stock overvalued right now?
Based on GuruFocus' analysis, Lumosa Therapeutics Co (ROCO:6535) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$130.93, compared to a current price of NT$107.50 — trading 17.9% below its estimated fair value. The current Current Ratio is 7.37, which is near median its 10-year median of 7.15 and 89% above the Biotechnology industry median of 3.90. Lumosa Therapeutics Co's overall GF Score™ is 72/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Lumosa Therapeutics Co (ROCO:6535), the current Current Ratio is 7.37 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lumosa Therapeutics Co (ROCO:6535) Overvalued in 2026?
Based on GuruFocus' analysis, Lumosa Therapeutics Co stock appears to be undervalued.
The current stock price of NT$107.50 is trading 17.9% below its estimated GF Value™ of NT$130.93.
GuruFocus considers Lumosa Therapeutics Co to be Modestly Undervalued.
Key valuation signals for ROCO:6535:
Current Ratio: 7.37 (near median its 10-year median of 7.15)
GF Value™: NT$130.93 vs. price of NT$107.50 (17.9% below fair value)
Industry Position: 89% above the Biotechnology median (#427 of 1410)
No single metric tells the full story. See the ROCO:6535 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lumosa Therapeutics Co Ltd develops new drugs. The company is engaged in the development of drugs for unmet medical needs in the fields of oncology and Neuroscience. Geographically, it derives a majority of its revenue from Taiwan and also has a presence in Asia, and America. The product pipeline of the company is Neuroscience, which includes LT 1001 for Postoperative Pain, LT 3001 for Acute Ischemic Stroke, LT 5001 for Uremic Pruritus, LT 6001 for Neurological disorder, and Oncology, including LT 2003 for Solid Tumor. It generates revenue from sales of goods.
72GF Score
Get the complete analysis for ROCO:6535
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6535 has been successfully added to your 
